Isosteviol Acyl-β-D-glucuronide Triacetate
- Empirical Formula: C32H44O12
- Molecular Weight: 0
- Update Date: 2023-04-23 13:52:06
What is Isosteviol Acyl-β-D-glucuronide Triacetate?
The Uses of Isosteviol Acyl-β-D-glucuronide Triacetate
Isosteviol Acyl-β-D-glucuronide Triacetate is an intermediate used in the synthesis of Isosteviol Acyl-β-D-glucuronide Potassium Salt (I902218), which is a metabolite of Isosteviol (I902200).
Properties of Isosteviol Acyl-β-D-glucuronide Triacetate
| solubility | Chloroform; Dichloromethane; Ethyl Acetate |
| form | Solid |
| color | White |
Safety information for Isosteviol Acyl-β-D-glucuronide Triacetate
Computed Descriptors for Isosteviol Acyl-β-D-glucuronide Triacetate
New Products
Dexamethasone Sodium Phosphate p-Anisaldehyde m-Tolualdehyde 2-Bromobenzaldehyde 4-Fluorobenzaldehyde 1-Propyl-4-piperidone 3-Amino-3-(3-fluorophenyl)propanoic acid Raloxifene EP Impurity D N-Nitroso Nortriptyline Nitroso Irbesartan 2-(p-Tolyl)acetaldehyde Sulfonic acid Impurity 2,2-dibromo-1-cyclopropyl-2-(2-fluorophenyl)ethan-1-one 5-Chloro-2-Methoxy-4-Picoline 2-Amino-6-nitrobenzoic Acid (6-Nitroanthranilic acid) Cis-3,5 Diacetoxy-1-cyclopentene 3-Bromo-2-Methoxy-4-Methylpyridine 2-Amino-5-Chloro-3-Nitro-6-picoline 3-Methoxy-5-methylpyrazin-2-amine Pentachlorobenzonitrile Budesonide Nicotinic acid RAPAMYCIN Alpha CyclodextrinYou may like
-
88660-53-1 >99%View Details
88660-53-1 -
12029-98-0 >98%View Details
12029-98-0 -
1177-87-3 Dexamethasone Acetate >98%View Details
1177-87-3 -
Hydrocortisone 50-23-7 >98%View Details
50-23-7 -
106-43-4 Parachlorotoluene >99%View Details
106-43-4 -
Pyrrolidin >98%View Details
123-75-1 -
cis-p-Menth-2,8-diene-1-ol 7212-40-0 >98%View Details
7212-40-0 -
Para Chloro toluene (PCT) 106-43-4 >99%View Details
106-43-4
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.
